Clinical trials: Hepatic Cirrhosis
Non Alcoholic Fatty Liver Disease, Type 2 Diabetes
Pathophysiological Implications of the Incretin Hormones in Patients With Liver Disease With and Without Diabetes
The main objective of this study is to analyze the pathophysiological implications of glucagon and the incretin hormones in patients with liver disease (Non alcoholic fatty liver disease (NAFLD) or cirrhosis) with and without…
- Conditions
- Non Alcoholic Fatty Liver Disease, Type 2 Diabetes, Liver Cirrhosis
- Trial name
- NCT01492283
- Testing
- OGTT, IIGI
- Where
- Denmark
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
Cirrhosis
Primary Prophylaxis of Gastric Varix Bleed
In patients who have never bled from gastric varix (GOV2 and IGV1), cyanoacrylate injection will be better than both beta-blocker therapy and no treatment in prevention of gastric variceal bleed.
- Trial name
- NCT00905996
- Testing
- Endoscopic cyanoacrylate injection, Beta-blocker (propranolol)
- Where
- India
- Volunteers
- 74 people
- Sponsor
- Govind Ballabh Pant Hospital
Cirrhosis
The Cirrhosis Outpatient Optimization, Readmission & Safety Study
A prospective series comparing care incorporating home monitoring and liver care coordination to conventional care for patients with cirrhosis.
- Trial name
- Vivify (NCT02457988)
- Testing
- Vivify Kit
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- University of California, Los Angeles
Chronic Hepatitis B Virus (HBV) Infection, Liver Fibrosis
Non-Invasive Model for Fibrosis Regression in HBV Patients
A total of 1000 chronic hepatitis B (CHB) patients with liver biopsy performed at least 1 year after antiviral therapy are retrospectively enrolled. All the patients received NAs treatment.
- Trial name
- NCT06874127
- Testing
- Nucleos(t)ide Analogs (NA)
- Where
- China
- Volunteers
- 1,100 people
- Sponsor
- Beijing Friendship Hospital
Hepatitis C, Chronic, Cirrhosis, Decompensated
Effects of Harvoni in Patients With Decompensated Cirrhosis Due to Hepatitis C Genotype 1 Infection
There are now several licensed drug treatments for patients with HCV infection. These medications have been shown to be very effective in getting rid of the virus in patients with HCV infection including those with early stages…
- Trial name
- NCT02597166
- Testing
- Ledipasvir/Sofosbuvir
- Where
- Canada
- Volunteers
- 14 people
- Sponsor
- University Health Network, Toronto
Hepatitis C Infection, Viruses
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
The purpose of this study is to test the safety and efficacy of Civacir® to prevent the recurrence of Hepatitis C Virus (HCV) after liver transplant.
- Conditions
- Hepatitis C Infection, Viruses, Hepatocellular Carcinoma, Hepatitis, Viral, Human
- Trial name
- NCT01804829
- Testing
- Civacir® 10%
- Where
- 23 sites in United States
- Volunteers
- 80 people
- Sponsor
- Biotest Pharmaceuticals Corporation
Liver Cirrhosis
Fecal Microbiota Transplantation in Decompensated Cirrhosis
Cirrhosis of the liver is the culmination point of long-standing chronic liver disease hallmarked by the cardinal features of liver fibrosis and portal hypertension.
- Trial name
- NCT04842539
- Testing
- Fecal Microbiota Transplantation, Standard of care
- Where
- India
- Volunteers
- 36 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Portal Hypertension
A Combined Model Based on Spleen Stiffness, Liver Stiffness and Platelets for Assessing Portal Hypertension in Compensated Cirrhosis (CHESS2202)
Portal hypertension contributed to the main complications of liver cirrhosis. Currently, hepatic venous pressure gradient (HVPG) was the reference standard for evaluating portal pressure in patients with cirrhosis.
- Trial name
- NCT05251272
- Testing
- Hepatic venous pressure gradient
- Where
- 5 sites in China
- Volunteers
- 300 people
- Sponsor
- Hepatopancreatobiliary Surgery Institute of Gansu Province
Cirrhosis, Ascites
Effects of Long Term Albumin 20% Administration in Patients With Cirrhosis and Ascites.
Effects of long term albumin administration on the cardiocirculatory and renal function and hepatic hemodynamics in patients with advanced cirrhosis and ascites.
- Trial name
- NCT00968695
- Testing
- Albumin
- Where
- 6 sites in Spain
- Volunteers
- 33 people
- Sponsor
- Instituto Grifols, S.A.
Liver Fibrosis Due to NASH
Safety and Efficacy of Simtuzumab (SIM, GS-6624) in Adults With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)
The primary objective of this study is to evaluate whether SIM (formerly referred to as GS-6624) is effective at preventing the histologic progression of liver fibrosis and the clinical progression to cirrhosis in participants…
- Trial name
- NCT01672866
- Testing
- SIM
- Where
- 68 sites in United States, Belgium and 7 more
- Volunteers
- 222 people
- Sponsor
- Gilead Sciences
Liver Fibroses, HepatoCellular Carcinoma
Long-term Outcomes of Chronic Hepatitis C Patients Post Sofosbuvir-based Treatment
Primary Objective: To evaluate the long-term outcomes including liver related morbidity, mortality and hepatocellular carcinoma (HCC) development as compared to those of historical control with interferon(IFN)-based treatment.
- Conditions
- Liver Fibroses, HepatoCellular Carcinoma, Cryoglobulinemia, Metabolic Disease
- Trial name
- LONGHEAD (NCT03042520)
- Testing
- Observation only
- Where
- 26 sites in South Korea, Taiwan
- Volunteers
- 200 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Cirrhosis
High Versus Low Target Mean Arterial Pressure in Septic Shock in Critically Ill Cirrhotics
Study Design: A randomized controlled study. The study will be conducted on patients admitted to Department of Hepatology from April 2017 to October 2017 at ILBS, New Delhi Study group will comprise of patients critically ill…
- Trial name
- NCT03145168
- Testing
- High Target Mean Arterial Pressure, Low Target Mean Arterial Pressure
- Where
- India
- Volunteers
- 150 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Hepatocellular Carcinoma, Liver Cirrhosis
Liver and Spleen Stiffness to Predict the Presence of Esaphageal Varices in Cirrhotic With Advanced HCC
Elasto-HCC is a prospective, uncontrolled, multicenter observational study involving several hepatology centers in Italy. Patients with liver cirrhosis and advanced hepatocellular carcinoma (HCC) who will need to undergo systemic…
- Conditions
- Hepatocellular Carcinoma, Liver Cirrhosis, Portal Hypertension
- Trial name
- ELASTO-HCC (NCT06773260)
- Testing
- Liver and Spleen stiffness measurement.
- Where
- 12 sites in Italy
- Volunteers
- 150 people
- Sponsor
- Azienda Ospedaliero Universitaria Policlinico Modena
Fibrosis, Liver
Screening for Chronic Liver Diseases in General Population
Improving the care of patients with liver diseases in primary care and will allow patients with chronic liver disease to benefit from a course appropriate care.
- Trial name
- HEPGEN (NCT06366425)
- Testing
- Blood sample then fibroscan
- Where
- France
- Volunteers
- 260 people
- Sponsor
- University Hospital, Montpellier
Primary Biliary Cholangitis
EXerCise Intervention in cholesTatic LivEr Disease: The EXCITED Study
A prospective, single centre, single-arm, pilot study investigating the safety and efficacy of a 12-week remotely-monitored home-based exercise program in patients with refractory fatigue (based on PBC-40 Quality of Life measure)…
- Trial name
- EXCITED (NCT04265235)
- Testing
- Home-based exercise program
- Where
- United Kingdom
- Volunteers
- 31 people
- Sponsor
- University of Birmingham
Hepatitis C Virus Infection
Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic HCV Infection
The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of sofosbuvir/velpatasvir (SOF/VEL) fixed dose combination (FDC) for 12 weeks in adults with chronic genotype 1, 2, 4, 5, or 6 hepatitis…
- Trial name
- ASTRAL-1 (NCT02201940)
- Testing
- SOF/VEL
- Where
- 80 sites in United States, Belgium and 7 more
- Volunteers
- 741 people
- Sponsor
- Gilead Sciences
Cholangitis, Liver Cirrhosis, Biliary
Retrospective Study About Primary Biliary Cholangitis During January 2001 to July 2016 at West China Hospital
Retrospective study of all patients diagnosed with primary biliary cholangitis during January 2001 to July 2016 at West China Hospital by review of medical records.
- Conditions
- Cholangitis, Liver Cirrhosis, Biliary, Cholestasis, Liver Diseases
- Trial name
- NCT02917408
- Where
- China
- Volunteers
- 769 people
- Sponsor
- Xiaoli Fan
HepatoCellular Carcinoma, Cirrhosis
Mutational Landscape in Hepatocellular Carcinoma
The MUTHEC project aims to describe the mutational and transcriptomic landscape of HCC treated by curative treatments (resection, radio frequency ablation, transplantation) as well as advanced HCC together with the analysis of…
- Trial name
- MUTHEC (NCT03071458)
- Where
- France
- Volunteers
- 808 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Cirrhosis, Portal Hypertension
Emricasan, an Oral Caspase Inhibitor, in Subjects With NASH Cirrhosis and Severe Portal Hypertension
This is a multicenter, randomized, double-blind, placebo-controlled trial involving subjects with NASH cirrhosis and severe portal hypertension (defined as HVPG ≥12 mmHg as determined by the central reader assigned to this…
- Conditions
- Cirrhosis, Portal Hypertension, Non-alcoholic Steatohepatitis
- Trial name
- ENCORE-PH (NCT02960204)
- Testing
- Emricasan
- Where
- 37 sites in United States, Germany and 1 more
- Volunteers
- 263 people
- Sponsor
- Histogen
Hepatitis C Recurrence After Liver Transplant
The Impact of Everolimus Based Immunosuppression in the Evolution of Hepatitis C Fibrosis After Liver Transplantation
Background: Hepatitis C recurrence, which invariably occurs in viremic liver transplant (LT) recipients, associated with accelerated liver fibrosis leading to established graft cirrhosis in 40-20% of patients in 5 years with…
- Trial name
- NCT01707849
- Testing
- EVL arm, MMF arm
- Where
- Spain
- Volunteers
- 18 people
- Sponsor
- Hospital Vall d'Hebron
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.